Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Failed drug program
Biotech
PepGen ends all DMD work after phase 2 trial falls flat
PepGen’s exon 51-skipping oligonucleotide PGN-EDO51 only increased dystrophin to 0.59% of normal levels in four patients in the 10-mg/kg cohort.
Darren Incorvaia
May 28, 2025 5:30pm
Lundbeck slashes value of $250M Abide buyout after pain setback
Oct 24, 2024 7:20am
Eliem shuts down final drug program 5 months after major layoffs
Jul 20, 2023 9:05am
Novartis axes obesity drug as high-risk, high-reward bet fails
Jul 18, 2023 5:47am
Safety signal sinks Theseus' cancer program—and its share price
Jul 14, 2023 7:20am
KalVista axes angioedema program over raised enzyme levels
Oct 4, 2022 10:32am
